Pharmacological treatment and staging in bipolar disorder: Evidence from clinical practice

Revista Brasileira de Psiquiatria

Volumn 37, Issue 2, 2015, Pages 121-125

  Goi, Pedro D ^a   Bücker, Joana ^a   Vianna Sulzbach, Mireia ^a   Rosa, Adriane R ^a,b   Grande, Iria ^c   Chendo, Ines ^d   Sodré, Leonardo A ^a   Kauer Sant’Anna, Marcia ^a   Silveira, Leonardo ^a   Kunz, Mauricio ^a   Ceresér, Keila M ^a   Gama, Clarissa S ^a   Massuda, Raffael ^a,e  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Anticonvulsants; Antidepressants; Antipsychotics; Bipolar mood disorders; Diagnosis and classification

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; COMORBIDITY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; SEMI STRUCTURED INTERVIEW; YOUNG MANIA RATING SCALE; BRAZIL; CLASSIFICATION; CLINICAL PROTOCOL; DISEASE COURSE; EVIDENCE BASED PRACTICE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAZIL; CLINICAL PROTOCOLS; CLOZAPINE; DISEASE PROGRESSION; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PRACTICE PATTERNS, PHYSICIANS'; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS;

EID: 84931456246     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2014-1554     Document Type: Article

References (29)

1. Caccamo MA, Eckman PM. Pharmacologic therapy for New York Heart Association class IV heart failure. Congest Heart Fail. 2011;17:213-9.
2. Piris A, Mihm MC Jr, Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol. 2011;38:394-400.
3. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575-86.
4. Gama CS, Kunz M, Magalhães PV, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr. 2013;35:70-4.
5. Berk M, Berk L, Udina M, Moylan S, Stafford L, Hallam K, et al. Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale. Aust N Z J Psychiatry. 2012;46:92-9.
6. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804-17.
7. Kapczinski F, Dias VV, Kauer-Sant’Anna M, Brietzke E, Vazquez GH, Vieta E, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1366-71.
8. Kauer-Sant’Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12:447-58.
9. Lisy ME, Jarvis KB, DelBello MP, Mills NP, Weber WA, Fleck D, et al. Progressive neurostructural changes in adolescent and adult patients with bipolar disorder. Bipolar Disord. 2011;13:396-405.
10. Berk M, Berk L, Dodd S, Cotton S, Macneil C, Daglas R, et al. Stage managing bipolar disorder. Bipolar Disord. 2014;16:471-7.
11. Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9:671-8.
12. Kapczinski F, Dias VV, Kauer-Sant’Anna M, Frey BN, Grassi-Oliveira R, Colom F, et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother. 2009;9:957-66.
13. Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 2011;13:87-98.
14. Reinares M, Colom F, Rosa AR, Bonnin CM, Franco C, Solé B, et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord. 2010;123:81-6.
15. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research; 2002.
16. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-35.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
18. Rosa AR, Sánchez-Moreno J, Martínez-Aran A, Salamero M, Torrent C, Reinares M, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.
19. Rosa AR, Magalhaes PV, Czepielewski L, Sulzbach MV, Goi PD, Vieta E, et al. Clinical staging in bipolar disorder: focus on cognition and functioning. J Clin Psychiatry. 2014;75:e450-6.
20. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry. 1999;156:1264-6.
21. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment- resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-96.
22. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-10.
23. Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, et al. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry. 2006;67:95-101.
24. Vieta E, Popovic D, Rosa AR, Sole´ B, Grande I, Frey BN, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry. 2013;28:21-9.
25. Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and antiinflammatory balance. Rev Bras Psiquiatr. 2011;33:268-74.
26. Andreazza AC, Kapczinski F, Kauer-Sant’Anna M, Walz JC, Bond DJ, Goncalves CA, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34:263-71.
27. Rosa AR, González-Ortega I, González-Pinto A, Echeburúa E, Comes M, Martínez-Áran A, et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand. 2012;125:335-41.
28. Lopez-Jaramillo C, Lopera-Vasquez J, Gallo A, Ospina-Duque J, Bell V, Torrent C, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord. 2010;12:557-67.
29. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1-44.